EVIDENCE LEVEL 1B
Hyperthermia Treatment for
Regional Hyperthermia added to chemotherapy doubles the length of overall survival in patients with high-risk localised soft tissue sarcoma, and significantly improves the 9 year overall survival. (EORTC trial, ESMO 2015).
Phase III EORTC trial (EORTC 62961/ESHO; registered: NCT00003052)
5 Years Overall Survival %
Local Progression Free Survival %
Disease Free Survival %
To know more download our white paper with all the 1st level evidence data and research on Hypethermia Treatment for Sarcoma
It was also shown to significantly improve the 9-year overall survival with no change in short term or long term toxicity between the two groups. In other clinical trials, regional hyperthermia when combined with chemotherapy, improved quality of life and survival statistics, and has scored well on several cost effective analysis.
“These findings strongly support adding regional hyperthermia to standard neoadjuvant chemotherapy in patients with localised high-risk soft tissue sarcoma. Induction with hyperthermia resulted in significantly increased Overall Survival (OS), Disease Free Progression (DFS), and Local Progression Free Survival (LPFS).”
Want to read more on the research supporting hyperthermia treatment of sarcoma?
Download the white paper with all of the research and data.
Please fill up the contact form to request more information or schedule an appointment with us.
Let us hold your hand through your healing journey.